These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20685246)

  • 1. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.
    Introna M; Pievani A; Borleri G; Capelli C; Algarotti A; Micò C; Grassi A; Oldani E; Golay J; Rambaldi A
    Biol Blood Marrow Transplant; 2010 Nov; 16(11):1603-7. PubMed ID: 20685246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.
    Introna M; Franceschetti M; Ciocca A; Borleri G; Conti E; Golay J; Rambaldi A
    Bone Marrow Transplant; 2006 Nov; 38(9):621-7. PubMed ID: 16980990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
    Rocha V; Labopin M; Sanz G; Arcese W; Schwerdtfeger R; Bosi A; Jacobsen N; Ruutu T; de Lima M; Finke J; Frassoni F; Gluckman E; ;
    N Engl J Med; 2004 Nov; 351(22):2276-85. PubMed ID: 15564544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
    Laughlin MJ; Eapen M; Rubinstein P; Wagner JE; Zhang MJ; Champlin RE; Stevens C; Barker JN; Gale RP; Lazarus HM; Marks DI; van Rood JJ; Scaradavou A; Horowitz MM
    N Engl J Med; 2004 Nov; 351(22):2265-75. PubMed ID: 15564543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
    Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
    Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.
    Li Y; Qu YH; Wu YF; Wang XP; Wei J; Huang WG; Zhou DH; Fang J; Huang K; Huang SL
    Ann Hematol; 2011 Aug; 90(8):873-85. PubMed ID: 21234566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.
    Linn YC; Niam M; Chu S; Choong A; Yong HX; Heng KK; Hwang W; Loh Y; Goh YT; Suck G; Chan M; Koh M
    Bone Marrow Transplant; 2012 Jul; 47(7):957-66. PubMed ID: 21986635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
    Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
    Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy.
    Niam M; Linn YC; Fook Chong S; Lim TJ; Chu S; Choong A; Yong HX; Suck G; Chan M; Koh M
    Exp Hematol; 2011 Sep; 39(9):897-903.e1. PubMed ID: 21703986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusions of recipient-derived cytokine-induced killer cells of donor origin eradicated residual disease in a relapsed leukemia patient after allo-hematopoietic stem cell transplantation.
    Zhong ZD; Luo Y; Zou P; Zheng JE; Yao JX; Huang SA; Zhou DF; You Y
    Chin Med J (Engl); 2012 May; 125(9):1669-71. PubMed ID: 22800843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
    Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
    Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19
    Golay J; Martinelli S; Alzani R; Cribioli S; Albanese C; Gotti E; Pasini B; Mazzanti B; Saccardi R; Rambaldi A; Introna M
    Cytotherapy; 2018 Aug; 20(8):1077-1088. PubMed ID: 30093325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells.
    Li Y; Schmidt-Wolf IG; Wu YF; Huang SL; Wei J; Fang J; Huang K; Zhou DH
    Anticancer Res; 2010 Sep; 30(9):3493-9. PubMed ID: 20944128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unrelated umbilical cord blood transplantation for adults with haematological malignancies: results from a single Australian centre.
    Bradstock KF; Hertzberg MS; Kerridge IH; Svennilson J; McGurgan M; Huang G; Antonenas V; Gottlieb DJ
    Intern Med J; 2006 Jun; 36(6):355-61. PubMed ID: 16732860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an automated closed fluid management device for processing expanded cytokine-induced killer cells to use in immunotherapy programs for cancer.
    Giancola R; Olioso P; Di Riti M; Capone A; Contento A; Pompetti F; Iacone A
    Transfusion; 2008 Apr; 48(4):629-39. PubMed ID: 18208417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy.
    Lin SJ; Kuo ML
    Pediatr Hematol Oncol; 2011 Nov; 28(8):640-6. PubMed ID: 21970456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.